Convatec Group (MEX:CTEC1N) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:CTEC1N Convatec Group PLC MEX:CTEC1N
78 GF Score
Price MXN59.76
GF Value MXN67.64
! 4 Warning Signs
View Full Analysis

What is Convatec Group FFO?

FFO (Funds from operations) only applies to REITs.

MEX:CTEC1N
78GF Score
Convatec Group PLC MEX:CTEC1N
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Convatec Group (MEX:CTEC1N) Overvalued in 2026?

Based on GuruFocus' analysis, Convatec Group stock appears to be undervalued. The current stock price of MXN59.76 is trading 11.6% below its estimated GF Value™ of MXN67.64.

Key valuation signals for MEX:CTEC1N:

  • FFO:
  • GF Value™: MXN67.64 vs. price of MXN59.76 (11.6% below fair value)
  • GF Score™: 78/100 with 4 warning signs

No single metric tells the full story. See the MEX:CTEC1N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Convatec Group Business Description

Address 20 Eastbourne Terrace, 7th Floor, London, GBR, W2 6LG
Originally spun out of Bristol-Myers Squibb, Convatec designs, manufactures, and markets advanced wound care, ostomy, continence care, and infusion sets for the acute-care hospital and chronic-care home settings. Advanced wound care and ostomy supplies are the largest divisions, accounting for 32% and 28% of total revenue, respectively. Continence care has become a slightly smaller business (22% of revenue) following the decision to exit the acute care market, and infusion sets contribute 18% of consolidated revenue.
78GF Score

Get the complete analysis for MEX:CTEC1N

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN59.76
Price
MXN67.64
GF Value